Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Nektar Therapeutic Systems (NKTR) Com Stk Nil Par Value (CDI)

Sell:$16.49 Buy:$16.50 Change: $0.25 (1.54%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.25 (1.54%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
Change: $0.25 (1.54%)
Market closed |  Prices as at close on 17 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.

Contact details

455 Mission Bay Blvd S
United States
+1 (415) 4825300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.97 billion
Shares in issue:
183.80 million
United States
US dollar

Key personnel

  • Howard Robin
    President, Chief Executive Officer, Director
  • Gilbert Labrucherie
    Chief Financial Officer, Chief Operating Officer, Senior Vice President
  • Jillian Thomsen
    Senior Vice President - Finance, Chief Accounting Officer
  • Mark Wilson
    Senior Vice President, General Counsel
  • Brian Kotzin
    Senior Vice President - Clinical Development and Head of Immunology
  • John Northcott
    Senior Vice President and Chief Commercial Officer
  • Dimitry Nuyten
    Senior Vice President, Chief Medical Officer
  • Jonathan Zalevsky
    Chief Research and Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.